Alveus Therapeutics vs Profluent Bio

Side-by-side comparison of AI visibility scores, market position, and capabilities

Profluent Bio leads in AI visibility (37 vs 23)
Alveus Therapeutics logo

Alveus Therapeutics

EmergingBioTech

Pulmonary Disease

Alveus Therapeutics raised $150M Series A in 2025 for inhaled mRNA therapeutics targeting pulmonary diseases including idiopathic pulmonary fibrosis and COPD, bringing mRNA technology directly to the lung.

AI VisibilityBeta
Overall Score
D23
Category Rank
#1 of 1
AI Consensus
49%
Trend
up
Per Platform
ChatGPT
15
Perplexity
24
Gemini
15

About

Alveus Therapeutics is applying mRNA medicine to pulmonary diseases by developing inhaled mRNA formulations that deliver protein replacement or gene editing instructions directly to lung cells. Unlike systemic mRNA therapeutics that require IV infusion and liver targeting, Alveus's inhaled approach delivers mRNA locally to lung epithelial cells, enabling treatment of diseases like idiopathic pulmonary fibrosis (IPF), COPD, and cystic fibrosis with potentially lower doses and fewer systemic side effects.

Full profile
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
69%
Trend
up
Per Platform
ChatGPT
45
Perplexity
35
Gemini
38

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile

AI Visibility Head-to-Head

23
Overall Score
37
#1
Category Rank
#1
49
AI Consensus
69
up
Trend
up
15
ChatGPT
45
24
Perplexity
35
15
Gemini
38
31
Claude
37
33
Grok
31

Key Details

Category
Pulmonary Disease
AI Protein Design
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Alveus Therapeutics
Pulmonary Disease
Only Profluent Bio
AI Protein Design

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.